JP2022521173A5 - - Google Patents

Info

Publication number
JP2022521173A5
JP2022521173A5 JP2021547154A JP2021547154A JP2022521173A5 JP 2022521173 A5 JP2022521173 A5 JP 2022521173A5 JP 2021547154 A JP2021547154 A JP 2021547154A JP 2021547154 A JP2021547154 A JP 2021547154A JP 2022521173 A5 JP2022521173 A5 JP 2022521173A5
Authority
JP
Japan
Prior art keywords
erdafitinib
cancer
specifically
daily
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021547154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/053490 external-priority patent/WO2020165181A1/en
Publication of JP2022521173A publication Critical patent/JP2022521173A/ja
Publication of JP2022521173A5 publication Critical patent/JP2022521173A5/ja
Priority to JP2025162216A priority Critical patent/JP2026016402A/ja
Withdrawn legal-status Critical Current

Links

JP2021547154A 2019-02-12 2020-02-11 癌治療 Withdrawn JP2022521173A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025162216A JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806.2 2019-02-12
EP19156806 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025162216A Division JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Publications (2)

Publication Number Publication Date
JP2022521173A JP2022521173A (ja) 2022-04-06
JP2022521173A5 true JP2022521173A5 (enExample) 2023-02-21

Family

ID=69467563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547154A Withdrawn JP2022521173A (ja) 2019-02-12 2020-02-11 癌治療
JP2025162216A Pending JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025162216A Pending JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Country Status (16)

Country Link
US (1) US20220168298A1 (enExample)
EP (1) EP3923942A1 (enExample)
JP (2) JP2022521173A (enExample)
KR (1) KR20210126654A (enExample)
CN (1) CN113423402A (enExample)
AU (1) AU2020223467B2 (enExample)
BR (1) BR112021015686A2 (enExample)
CA (1) CA3126959A1 (enExample)
IL (1) IL285466A (enExample)
JO (1) JOP20210216A1 (enExample)
MA (1) MA54932A (enExample)
MX (1) MX2021009670A (enExample)
PH (1) PH12021551949A1 (enExample)
SG (1) SG11202107850VA (enExample)
TW (1) TWI863962B (enExample)
WO (1) WO2020165181A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
KR20230152652A (ko) * 2020-12-11 2023-11-03 에라스카, 아이엔씨. 암 치료를 위한 병용 요법
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Similar Documents

Publication Publication Date Title
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN107519159A (zh) 复方组合物
TWI924837B (zh) 用於治療子宮漿液性癌之ｗｅｅ１化合物
KR102766876B1 (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
JP2024502446A5 (enExample)
JP2024539476A5 (enExample)
CN104540514B (zh) 治疗癌症相关性疲劳的组合物
JP2024531799A5 (enExample)
CN103263416A (zh) 一种吡啶胺化合物在制备适于口服给药的治疗肺癌的药物中的应用
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
WO2024041633A1 (zh) 一种稠环嘧啶类化合物的用途
CN113876777A (zh) 尼达尼布治疗异常新生血管形成骨关节疾病的方法
CN109106720B (zh) 西达本胺与依西美坦在制备用于治疗乳腺癌的联合用药物中的用途及联合用药物
WO2018201920A1 (zh) 龙虎人丹在制备预防和/或治疗肝纤维化药物中的应用
TWI922738B (zh) 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
CN115154448B (zh) 一种治疗不宁腿综合征的药物及其制备方法和应用
JP2003095981A (ja) 医薬組成物
CN114712427B (zh) 一种桃树根药物的应用
JP2009263384A (ja) Ｉ型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬
TW202241421A (zh) 菸鹼醯胺及含有其的組合物的製藥用途
TWI599371B (zh) 醫藥組合物用於製備治療檳榔使用失調之藥物上的用途
JP2023507764A5 (enExample)